News

Latest News

Stocks in Play

Dividend Stocks

ETFs

Breakout Stocks

Tech Insider

Forex Daily Briefing

US Markets

Stocks To Watch

The Week Ahead

SECTOR NEWS

Commodites

Commodity News

Metals & Mining News

Crude Oil News

Crypto News

M & A News

Newswires

OTC Company News

TSX Company News

Earnings Announcements

Dividend Announcements

Decision Gains Strength on Alliance with Paragon

Successful companies – like successful individuals – know the value of obtaining help in their endeavors. Los Angeles-based Decision Diagnostics Corp. (OTC:DECN) announced a four-year agreement with Paragon Sales and Markeing Inc., to support the national growth of both its branded and private label retail products, sold under its "Gen" brand, and our private label brands of Alltara!, ConsumerValue!, Infatig!, and Medicius!.

Such products will find their way onto shelves at Walmart, CVS, Walgreens, Costco and Cardinal Health.

Said DECN CEO Keith Berman, "Now that we have established our 'Gen' technologies to the stage where we can comfortably direct our focus to the more traditional sales channels."

Decision Diagnostics, established 16 years ago, is a diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of alternatives to legacy diabetic, proprietary, and pet testing glucose test strips.

Shares in DECN raced higher by 26.9% to 2.5 cents, on just over 2.5 million shares.